Therapy Areas: Cardiovascular
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
4 September 2026 - Thryv Therapeutics Inc, a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced on Thursday that it has entered into an exclusive, worldwide, royal...
Lilly to acquire Merida Biosciences in USD2.875bn deal
31 August 2026 - US pharmaceutical company Eli Lilly and Company (NYSE: LLY) on Monday announced that it has agreed to acquire Merida Biosciences, Inc., a biotechnology business developing precision b...
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
28 August 2026 - Medical technology company GE HealthCare (Nasdaq:GEHC) on Friday unveiled three additions to its Vivid cardiovascular ultrasound portfolio: Vivid Explorer, Vivid Advanced and Vivid Fo...
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
28 August 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) said on Friday that new analyses from the multinational MILOS study demonstrate the real-world impact of bempedoic acid, u...
Revier Therapeutics closes EUR6m seed financing and launches operations
26 August 2026 - German pharmaceutical company Revier Therapeutics announced on Tuesday the closing of a EUR6m seed financing and the launch of its operations.The company says that it has established ...
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
24 August 2026 - Medical technology company Tempus AI Inc (NASDAQ: TEM) reported on Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-ena...